Analysis of Circulating Tumor Markers in Blood
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorInstitut du Cancer de Montpellier - Val d'Aurelle
About this trial
The circulating tumoral biomarkers in the blood are the object of numerous researches for several decades. The potential clinical interests of these circulating biomarkers are diagnostic, prognostic, predictive of the efficiency of targeted therapies (according to the mutational profile of the cancer), and could allow the study of the mechanisms of resistance under process. In the multiplicity of these blood potential biomarkers joins a permanent evolution of the technological means used to detect them/to quantify, as well as to estimate their clinical utility.
Eligibility criteria
Qualifiers
Patient presenting an invasive tumoral pathology (proved or suspected), whatever is the location or the stage,
Man or woman ≥ 18 years,
Obtaining of the informed consent signed before any procedure of specific preselection on approval.
Disqualifiers
Private persons of freedom or under guardianship,
Patient whose regular follow-up is impossible for psychological, family, social or geographical reasons,
Pregnant woman and/or breast-feeding,
Unaffiliated patient to Social Protection System,
Trial design
Treatments tested in this trial
- Blood sampling
- Blood sampling C3
- Blood sampling C4/7/10/13
- Blood sampling C5
- Blood sampling C6
- Blood sampling C8
- Blood sampling C9
- Blood sampling C11 + FFPE
- Blood sampling C12
Treatment groups
992 Participants
are divided into 13 treatment groups13
Treatment groupsSee each treatment group below.
Sponsors and collaborators
Source ClinicalTrials.gov